Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
ACADEMIA
British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
British medical journal The Lancet is in the process of retracting a paper based on the JIKEI Heart Study on Novartis Pharma’s top-selling hypertension drug Diovan (valsartan), a Lancet spokesperson told Jiho. The Lancet is now drafting a retraction statement…
To read the full story
Related Article
- Jikei Concludes Event Data Unnatural in Diovan Study
December 15, 2014
ACADEMIA
- Non-HCPs Have Higher Expectations of Alzheimer’s Drugs than Specialists: Poll
October 7, 2024
- Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse
October 1, 2024
- KOL Calls for Public Support for Truvada’s PrEP Use against HIV
September 26, 2024
- Early Use of High-Dose Mecobalamin Extends Survival in ALS: IIT Data
September 20, 2024
- NCC, Eisai Confirm Tumor Shrinkage with E7820 Using J-PDX Models
September 17, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…